{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:55:32Z","timestamp":1791172532609,"version":"4.1.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1097\/qai.0b013e318189a753","type":"journal-article","created":{"date-parts":[[2008,10,30]],"date-time":"2008-10-30T07:10:03Z","timestamp":1225350603000},"page":"266-271","source":"Crossref","is-referenced-by-count":43,"title":["The Relationship Between Resistance and Adherence in Drug-Naive Individuals Initiating HAART Is Specific to Individual Drug Classes"],"prefix":"10.1097","volume":"49","author":[{"given":"Lily W Y","family":"Tam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia K S","family":"Chui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanson J","family":"Brumme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Bangsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio S G","family":"Montaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S","family":"Hogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P Richard","family":"Harrigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210131","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"R2-5-20210131","first-page":"659","article-title":"Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.","volume":"160","author":"Hogg","year":"1999","journal-title":"CMAJ"},{"key":"R3-5-20210131","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.","volume":"337","author":"Hammer","year":"1997","journal-title":"N Engl J Med"},{"key":"R4-5-20210131","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.283.18.2417","article-title":"Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.","volume":"283","author":"Hirsch","year":"2000","journal-title":"JAMA"},{"key":"R5-5-20210131","first-page":"656","article-title":"Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.","volume":"169","author":"Wood","year":"2003","journal-title":"CMAJ"},{"issue":"Suppl 2","key":"R6-5-20210131","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1086\/313855","article-title":"Determinants of virological response to antiretroviral therapy: implications for long-term strategies.","volume":"30","author":"Deeks","year":"2000","journal-title":"Clin Infect Dis"},{"key":"R7-5-20210131","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1086\/427192","article-title":"Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy.","volume":"191","author":"Harrigan","year":"2005","journal-title":"J Infect Dis"},{"key":"R8-5-20210131","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jac\/dkl386","article-title":"Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation.","volume":"58","author":"Braithwaite","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"R9-5-20210131","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/jac\/dkh162","article-title":"Paradoxes of adherence and drug resistance to HIV antiretroviral therapy.","volume":"53","author":"Bangsberg","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"R10-5-20210131","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/01.aids.0000199825.34241.49","article-title":"Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.","volume":"20","author":"Bangsberg","year":"2006","journal-title":"AIDS"},{"key":"R11-5-20210131","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1001\/jama.286.20.2568","article-title":"Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.","volume":"286","author":"Hogg","year":"2001","journal-title":"JAMA"},{"key":"R12-5-20210131","doi-asserted-by":"crossref","first-page":"810","DOI":"10.7326\/0003-4819-139-10-200311180-00008","article-title":"Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells\/L.","volume":"139","author":"Wood","year":"2003","journal-title":"Ann Intern Med"},{"key":"R13-5-20210131","first-page":"51","article-title":"Update of the drug resistance mutations in HIV-1: 2005.","volume":"13","author":"Johnson","year":"2005","journal-title":"Top HIV Med"},{"key":"R14-5-20210131","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/00002030-200205030-00012","article-title":"Intermittent use of triple combination therapy is predictive of mortality at baseline and after one year of follow-up.","volume":"16","author":"Hogg","year":"2002","journal-title":"AIDS"},{"key":"R15-5-20210131","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00126334-200004010-00016","article-title":"Adherence to triple therapy and viral load response.","volume":"23","author":"Low-Beer","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R16-5-20210131","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1086\/376835","article-title":"Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease.","volume":"188","author":"Alexander","year":"2003","journal-title":"J Infect Dis"},{"key":"R17-5-20210131","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables (with discussion).","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Ser Soc B"},{"key":"R18-5-20210131","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/jama.283.2.205","article-title":"Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team.","volume":"283","author":"Descamps","year":"2000","journal-title":"JAMA"},{"key":"R19-5-20210131","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jama.283.2.229","article-title":"Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.","volume":"283","author":"Havlir","year":"2000","journal-title":"JAMA"},{"key":"R20-5-20210131","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/00002030-200006160-00017","article-title":"Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine\/lamivudine\/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies.","volume":"14","author":"Maguire","year":"2000","journal-title":"AIDS"},{"key":"R21-5-20210131","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1097\/00002030-200109280-00025","article-title":"Changes in the rate of genotypic resistance to antiretroviral drugs in Spain.","volume":"15","author":"Gallego","year":"2000","journal-title":"AIDS"},{"key":"R22-5-20210131","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa012354","article-title":"Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.","volume":"346","author":"Walmsley","year":"2002","journal-title":"N Engl J Med"},{"key":"R23-5-20210131","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jclinepi.2004.04.002","article-title":"A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV.","volume":"57","author":"Grossberg","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"R24-5-20210131","doi-asserted-by":"crossref","first-page":"968","DOI":"10.7326\/0003-4819-134-10-200105150-00011","article-title":"A comparison study of multiple measures of adherence to HIV protease inhibitors.","volume":"134","author":"Liu","year":"2001","journal-title":"Ann Intern Med"},{"key":"R25-5-20210131","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/A:1011396711486","article-title":"Comparing objective measures of adherence to HIV antiretroviral therapy: electronic monitors and unannounced pill counts.","volume":"5","author":"Bangsberg","year":"2001","journal-title":"AIDS Behav"},{"key":"R26-5-20210131","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00002030-200401020-00017","article-title":"Are untimed antiretroviral drug levels useful predictors of adherence behavior?","volume":"18","author":"Liechty","year":"2004","journal-title":"AIDS"},{"key":"R27-5-20210131","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1086\/430387","article-title":"Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir\/ritonavir or nelfinavir.","volume":"191","author":"King","year":"2005","journal-title":"J Infect Dis"},{"key":"R28-5-20210131","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1097\/00002030-200309050-00011","article-title":"High levels of adherence do not prevent accumulation of HIV drug resistance mutations.","volume":"17","author":"Bangsberg","year":"2003","journal-title":"AIDS"},{"key":"R29-5-20210131","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1086\/420790","article-title":"Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates.","volume":"190","author":"Bangsberg","year":"2004","journal-title":"J Infect Dis"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00126334-200811010-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T12:15:08Z","timestamp":1738498508000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-200811010-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e318189a753","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}